This article is more than 5 years old. Information may no longer be current.
Fidaxomicin more economical vs. vancomycin for C. difficile associated-diarrhea
Fidaxomicin was the most rational fiscal strategy compared with vancomycin for Clostridium difficile-associated diarrhea in the hospital setting, according to data presented at the American Society of Health-System Pharmacists 46th Midyear Clinical Meeting.
Researchers aimed to assess the value of fidaxomicin (Dificid, Optimer Pharmaceuticals) in the hospital setting and pooled data for C. difficile-associated diarrhea (CDAD) cases from the 2009 US Healthcare Cost and Utilization Project.
For primary cases of CDAD, results indicated that 125 mg injectable vancomycin four times daily yielded a loss of $57 per day, whereas fidaxomicin saved $223 per day; 125 mg vancomycin capsules four times daily saved $45 per day, whereas fidaxomicin saved $325 per day; 250 mg vancomycin four times daily saved $136 per day, whereas fidaxomicin saved $416 per day.
Among secondary cases, 125 mg injectable vancomycin four times daily resulted in a loss of $492 per day, whereas fidaxomicin saved $772 per day; 125 mg vancomycin capsules four times daily saved $595 per day, whereas fidaxomicin saved $875 per day; 250 mg vancomycin four times daily saved $688 per day, whereas fidaxomicin saved $968 per day.
Overall, in most primary case scenarios, and for all secondary case scenarios examined, the estimated value of fidaxomicin exceeded the wholesale acquisition cost of $280 per day, according to the researchers.
For more information:
- Oganov AM. #4-277. Presented at: the 46th ASHP Midyear Clinical Meeting & Exhibition; Dec. 4-8, 2011; New Orleans.
Disclosure: This research was supported by Optimer Pharmaceuticals Inc.
 |
Follow InfectiousDiseaseNews.com on Twitter. |